{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T23:33:47Z","timestamp":1715211227379},"reference-count":8,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2014,4,24]],"date-time":"2014-04-24T00:00:00Z","timestamp":1398297600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1007\/s10067-014-2620-4","type":"journal-article","created":{"date-parts":[[2014,4,23]],"date-time":"2014-04-23T04:56:21Z","timestamp":1398228981000},"page":"1341-1346","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["New gout test: enhanced ex vivo cytokine production from PBMCS in common gout patients and a gout patient with Kearns-Sayre syndrome"],"prefix":"10.1007","volume":"33","author":[{"given":"Tim L.","family":"Jansen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dianne","family":"Berendsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tania O.","family":"Crisan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maartje C. P.","family":"Cleophas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mirian C. H.","family":"Janssen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leo A. B.","family":"Joosten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,4,24]]},"reference":[{"issue":"11","key":"2620_CR1","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1136\/annrheumdis-2012-201687","volume":"71","author":"M Doherty","year":"2012","unstructured":"Doherty M, Jansen TL, Nuki G et al (2012) Gout: why is this curable disease so seldom cured? Ann Rheum Dis 71(11):1765\u201370","journal-title":"Ann Rheum Dis"},{"key":"2620_CR2","doi-asserted-by":"crossref","first-page":"R158","DOI":"10.1186\/ar3898","volume":"14","author":"EE Mylona","year":"2012","unstructured":"Mylona EE, Mouktaroudi M, Crisan T et al (2012) Enhanced interleukin-1beta production of PBMCs from patients with gout after stimulation with toll-like receptor-2 ligands and urate crystals. Arthritis Res Ther 14:R158. doi: 10.1186\/ar3898","journal-title":"Arthritis Res Ther"},{"key":"2620_CR3","doi-asserted-by":"crossref","unstructured":"Stevenson M, Pandor 2009 Febuxostat for the treatment of hyperuricaemia in people with gout: a single technology appraisal. Health Technol Assess; Suppl 3: 37-42. doi: 10.3310\/hta13suppl3\/06","DOI":"10.3310\/hta13suppl3\/06"},{"key":"2620_CR4","unstructured":"Beard SM, Von Scheele BG, Nuki G, Pearson IV. Cost-effectiveness of febuxostat in chronic gout. Eur J Health Econ. Doi 10.1007\/210198-013-0486-z"},{"key":"2620_CR5","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/s10067-010-1457-8","volume":"29","author":"TL Jansen","year":"2010","unstructured":"Jansen TL, Richette P, Perez-Ruiz F et al (2010) International position paper on febuxostat. Clin Rheumatol 29:835\u2013840","journal-title":"Clin Rheumatol"},{"key":"2620_CR6","doi-asserted-by":"crossref","first-page":"R189","DOI":"10.1186\/ar4020","volume":"14","author":"DRW Kannangara","year":"2012","unstructured":"Kannangara DRW, Ramasamy SN, Indraratna PL et al (2012) Fractional clearance of urate: validation of measurement in spot-urine samples in healthy subjects and gouty patients. Arthritis Res & Ther 14:R189","journal-title":"Arthritis Res & Ther"},{"issue":"9","key":"2620_CR7","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1007\/s10067-006-0528-3","volume":"26","author":"MK Reinders","year":"2007","unstructured":"Reinders MK, Van Roon EN, Houtman PM, Brouwers JRBJ, Jansen TL (2007) Biochemical effectiveness of allopurinol and allopurinol-probenecid in previously benzbromarone-treated gout patients. Clin Rheumatol 26(9):1459\u20131465","journal-title":"Clin Rheumatol"},{"key":"2620_CR8","doi-asserted-by":"crossref","unstructured":"Fleishmann R, Kerr B, Yeh L-T, et al 2014 Pharmacodynamic, pharmacokinetic and safety evaluation of concomitant administration of lesinurad and febuxostat in gout patients with hyperuricemia. Rheumatology [Epub ahead of print] PMID 24509406","DOI":"10.1093\/rheumatology\/ket487"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-014-2620-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-014-2620-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-014-2620-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,9]],"date-time":"2019-08-09T20:24:09Z","timestamp":1565382249000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-014-2620-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4,24]]},"references-count":8,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["2620"],"URL":"https:\/\/doi.org\/10.1007\/s10067-014-2620-4","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,4,24]]}}}